First Tracks Biotherapeutics Inc(TRAX)
$50.53-1.80 (-3.44%)
TRAX
First Tracks Biotherapeutics Inc financials statements
$50.53
At close:-1.80 (-3.44%)
Want to see TRAX full AI Analyst Report?
First Tracks Biotherapeutics Inc (TRAX) Ratios
57 Followers
First Tracks Biotherapeutics Inc Ratios
TRAX's free cash flow for Q3 2026 was $-17.05M. For the 2026 fiscal year, TRAX's free cash flow was increased by $0.00 and operating cash flow was $-17.05M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 |
|---|---|---|---|
| Liquidity Ratios | |||
| Current Ratio | 10.20 | 10.78 | 21.87 |
| Quick Ratio | 10.20 | 10.78 | 21.87 |
| Cash Ratio | 7.68 | 3.40 | 1.97 |
| Solvency Ratio | -3.80 | -3.21 | -3.03 |
| Operating Cash Flow Ratio | -4.61 | -3.48 | -5.10 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 273.35M | $ 339.64M | $ 364.30M |
| Leverage Ratios | |||
| Debt-to-Assets Ratio | 0.04 | 0.04 | 0.04 |
| Debt-to-Equity Ratio | 0.05 | 0.04 | 0.04 |
| Debt-to-Capital Ratio | 0.05 | 0.04 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.15 | 1.13 | 1.08 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.41 | 0.00 | 0.51 |
| Net Debt to EBITDA | 1.27 | 0.60 | 0.16 |
| Profitability Margins | |||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 92.78% | 90.39% | 89.61% |
| Return on Assets (ROA) | -50.25% | -37.05% | -23.90% |
| Return on Equity (ROE) | -57.77% | -41.80% | -25.90% |
| Return on Capital Employed (ROCE) | -59.76% | -44.64% | -27.82% |
| Return on Invested Capital (ROIC) | -59.35% | -44.43% | -27.70% |
| Return on Tangible Assets | -50.25% | -37.05% | -23.90% |
| Earnings Yield | -25.16% | 0.00% | -16.08% |
| Efficiency Ratios | |||
| Receivables Turnover | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 44.88 | 40.25 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -8.13 | -9.07 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 8.13 | 9.07 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||
| Operating Cash Flow Per Share | -4.11 | 0.00 | -2.68 |
| Free Cash Flow Per Share | -4.12 | 0.00 | -2.70 |
| Dividend Paid and CapEx Coverage Ratio | -1642.83 | -351.41 | -115.25 |
| Capital Expenditure Coverage Ratio | -1642.83 | -351.41 | -115.25 |
| Operating Cash Flow Coverage Ratio | -10.13 | -7.84 | -5.22 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -21.66% | 0.00% | -14.21% |
| Valuation Ratios | |||
| Price-to-Earnings (P/E) Ratio | -3.98 | 0.00 | -6.22 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.30 | 0.00 | 1.61 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.62 | 0.00 | -7.04 |
| Price-to-Operating Cash Flow Ratio | -4.62 | 0.00 | -7.10 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 0.00 |
| Enterprise Value Multiple | -2.47 | 0.60 | -5.53 |
| Enterprise Value | 436.14M | -107.04M | 642.08M |
| EV to EBITDA | -2.47 | 0.60 | -5.53 |
| EV to Sales | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -3.05 | 0.85 | -6.84 |
| EV to Operating Cash Flow | -3.05 | 0.85 | -6.90 |
| Tangible Book Value Per Share | 8.27 | 0.00 | 11.79 |
| Shareholders’ Equity Per Share | 8.27 | 0.00 | 11.79 |
| Tax and Other Ratios | |||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -4.78 | 0.00 | -3.05 |
| Tax Burden | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.93 | 0.90 | 0.90 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.86 | 0.77 | 0.88 |
Currency in USD
